Literature DB >> 8033415

The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis.

A C Issekutz1, A Meager, I Otterness, T B Issekutz.   

Abstract

The mediators involved in leucocyte recruitment to joints during arthritis are not fully defined, but two important proinflammatory cytokines, IL-1 and tumour necrosis factor-alpha (TNF-alpha), are produced in joints in rheumatoid arthritis (RA). We investigated in the rat adjuvant arthritis model whether endogenous IL-1 and TNF-alpha contribute to joint inflammation and polymorphonuclear leucocyte (PMNL) and T lymphocyte infiltration. The migration of 51Cr-labelled rat blood PMNL and 111In-labelled T lymphocytes to the joints of rats with adjuvant arthritis was measured along with plasma protein extravasation, which was quantified using 125I-labelled human albumin. Rats with active arthritis of 5 days' duration received i.p. non-immune serum, polyclonal neutralizing anti-serum to rat TNF-alpha, antiserum to IL-1 alpha and IL-1 beta, or both anti-TNF plus anti-IL-1 for 5 days. Treatment with anti-IL-1 alpha and IL-1 beta did not affect plasma protein extravasation, or PMNL or T lymphocyte accumulation in the joints (i.e. talar joint, hind paws, and tail) despite the fact that this treatment inhibited 80-90% of the PMNL migration into dermal sites injected with IL-1 alpha or IL-1 beta. In contrast, anti-TNF-alpha treatment significantly improved clinical scores, decreased plasma protein extravasation by 60-80%, inhibited PMNL accumulation by 40-50% and decreased T lymphocyte accumulation by 30-50%. Treatment with anti-IL-1, together with anti-TNF-alpha, significantly potentiated the inhibition of T lymphocyte accumulation observed with anti-TNF-alpha alone. These results indicate that endogenous TNF-alpha production may play an important role in the inflammatory changes and leucocyte recruitment in this experimental model of human arthritis, while IL-1 may have a less important role in leucocyte recruitment to these joints.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033415      PMCID: PMC1534798          DOI: 10.1111/j.1365-2249.1994.tb06574.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Harvesting the noncirculating pool of polymorphonuclear leukocytes in rats by hetastarch exchange transfusion (HET): yield and functional assessment.

Authors:  J H Williams; K M Moser; T Ulich; M S Cairo
Journal:  J Leukoc Biol       Date:  1987-11       Impact factor: 4.962

2.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

Review 3.  Biochemical mechanisms of articular destruction.

Authors:  C L Mainardi
Journal:  Rheum Dis Clin North Am       Date:  1987-08       Impact factor: 2.670

4.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation.

Authors:  C V Wedmore; T J Williams
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

Review 5.  Progress in the understanding of inducible models of chronic arthritis.

Authors:  F C Breedveld; D E Trentham
Journal:  Rheum Dis Clin North Am       Date:  1987-12       Impact factor: 2.670

6.  Elevated levels of TNF in the joints of adjuvant arthritic rats.

Authors:  T Smith-Oliver; L S Noel; S S Stimpson; D P Yarnall; K M Connolly
Journal:  Cytokine       Date:  1993-07       Impact factor: 3.861

7.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

8.  Synergy between tumour necrosis factor alpha and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation.

Authors:  Z Wankowicz; P Megyeri; A Issekutz
Journal:  J Leukoc Biol       Date:  1988-04       Impact factor: 4.962

9.  Vascular responses during acute neutrophilic inflammation. Their relationship to in vivo neutrophil emigration.

Authors:  A C Issekutz
Journal:  Lab Invest       Date:  1981-11       Impact factor: 5.662

10.  Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma.

Authors:  T B Issekutz; J M Stoltz; P vd Meide
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

View more
  19 in total

Review 1.  Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Amelioration of oxidative and inflammatory changes by Swertia chirayita leaves in experimental arthritis.

Authors:  Harsha Lad; Deepak Bhatnagar
Journal:  Inflammopharmacology       Date:  2016-10-14       Impact factor: 4.473

3.  The protein LJM 111 from Lutzomyia longipalpis salivary gland extract (SGE) accounts for the SGE-inhibitory effects upon inflammatory parameters in experimental arthritis model.

Authors:  Renata Grespan; Henrique P Lemos; Vanessa Carregaro; Waldiceu A Verri; Fabricio O Souto; Carlo J F de Oliveira; Clarissa Teixeira; José Marcos Ribeiro; Jesus G Valenzuela; Fernando Q Cunha
Journal:  Int Immunopharmacol       Date:  2012-02-21       Impact factor: 4.932

4.  Cytokine and nitric oxide production in the acute phase of bacterial cell wall-induced arthritis.

Authors:  J W Fuseler; E M Conner; J M Davis; R E Wolf; M B Grisham
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

5.  Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis.

Authors:  S J Oliver; S L Freeman; L G Corral; C J Ocampo; G Kaplan
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease.

Authors:  A C Issekutz; L Ayer; M Miyasaka; T B Issekutz
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

Review 7.  Role of cytokines in experimental arthritis.

Authors:  F M Brennan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis.

Authors:  H Schädlich; J Ermann; M Biskop; W Falk; F Sperling; A Jüngel; J Lehmann; F Emmrich; U Sack
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

9.  Female temperament, tumor development and life span: relation to glucocorticoid and tumor necrosis factor alpha levels in rats.

Authors:  Sonia A Cavigelli; Jeanette M Bennett; Kerry C Michael; Laura Cousino Klein
Journal:  Brain Behav Immun       Date:  2007-12-21       Impact factor: 7.217

10.  Tumor necrosis factor priming of peripheral blood neutrophils from rheumatoid arthritis patients.

Authors:  I C Kowanko; A Ferrante; G Clemente; P P Youssef; M Smith
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.